ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs MXN
16.7804
-0.08%
Brent Oil
82.585
-1.63%
Bitcoin
60,543.12
-3.97%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) Noticias

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ARQT
FechaHoraFuenteTítuloSímboloCompañía
03/05/202415:00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
29/04/202415:00GlobeNewswire Inc.Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:ARQTArcutis Biotherapeutics Inc
10/04/202407:00GlobeNewswire Inc.Arcutis Appoints David Topper as Chief Financial OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
01/04/202406:00GlobeNewswire Inc.Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamNASDAQ:ARQTArcutis Biotherapeutics Inc
28/03/202407:00GlobeNewswire Inc.Arcutis to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
11/03/202407:00GlobeNewswire Inc.Arcutis Promotes Todd Tucker to Chief Human Resources OfficerNASDAQ:ARQTArcutis Biotherapeutics Inc
10/03/202415:00GlobeNewswire Inc.Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
09/03/202415:00GlobeNewswire Inc.New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier DysfunctionNASDAQ:ARQTArcutis Biotherapeutics Inc
06/03/202416:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202416:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202415:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202415:00GlobeNewswire Inc.Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:ARQTArcutis Biotherapeutics Inc
04/03/202407:00GlobeNewswire Inc.Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual MeetingNASDAQ:ARQTArcutis Biotherapeutics Inc
01/03/202415:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARQTArcutis Biotherapeutics Inc
29/02/202416:00GlobeNewswire Inc.Arcutis to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
28/02/202422:30GlobeNewswire Inc.Arcutis Announces Pricing of $150 Million Public OfferingNASDAQ:ARQTArcutis Biotherapeutics Inc
28/02/202415:10GlobeNewswire Inc.Arcutis Announces Proposed Public OfferingNASDAQ:ARQTArcutis Biotherapeutics Inc
28/02/202415:00GlobeNewswire Inc.Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in JapanNASDAQ:ARQTArcutis Biotherapeutics Inc
27/02/202415:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ARQTArcutis Biotherapeutics Inc
27/02/202406:48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARQTArcutis Biotherapeutics Inc
27/02/202404:50GlobeNewswire Inc.Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:ARQTArcutis Biotherapeutics Inc
16/02/202407:00GlobeNewswire Inc.Arcutis to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ARQTArcutis Biotherapeutics Inc
15/02/202415:19Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:ARQTArcutis Biotherapeutics Inc
13/02/202408:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARQTArcutis Biotherapeutics Inc
08/02/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ARQTArcutis Biotherapeutics Inc
31/01/202416:22Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ARQTArcutis Biotherapeutics Inc
31/01/202407:00GlobeNewswire Inc.Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
29/01/202407:00GlobeNewswire Inc.Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 TrialNASDAQ:ARQTArcutis Biotherapeutics Inc
22/01/202407:00GlobeNewswire Inc.ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United StatesNASDAQ:ARQTArcutis Biotherapeutics Inc
14/01/202403:00GlobeNewswire Inc.ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical SteroidsNASDAQ:ARQTArcutis Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ARQT

Su Consulta Reciente

COIN
CKSUSD
USOTC
QMIS
QMIS Finance Securities (CE)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados